Surrozen Provides Second Quarter 2023 Financial Results
09 août 2023 16h05 HE
|
Surrozen, Inc.
SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers continues to enroll with safety data expected by the end of 2023 SZN-1326 Phase 1a clinical trial in...
Surrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic Stroke
05 juin 2023 08h30 HE
|
Surrozen, Inc.
In a preclinical model of ischemic stroke, systemic delivery of a selective Fzd4 Wnt antibody strongly reduced blood-brain-barrier leakage, death of surrounding brain tissue, tissue swelling, while...
Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates
10 mai 2023 16h05 HE
|
Surrozen, Inc.
Enrollment ongoing in SZN-043 Phase 1a clinical trial in people with chronic liver disease and in healthy volunteers with safety data expected by the end of 2023 Enrollment ongoing in SZN-1326 Phase...
Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt
05 avr. 2023 08h30 HE
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the...
Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress
22 mars 2023 16h01 HE
|
Surrozen, Inc.
Enrolled first patient in SZN-043 Ph 1a clinical trial in chronic liver disease with data expected by the end of 2023 Expect to begin SZN-043 Ph1b clinical trial in severe alcoholic hepatitis in 2024...
Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023
20 mars 2023 16h30 HE
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), today announced that it will report fourth quarter and full year 2022...
Surrozen to Present at the 41st Annual J.P. Morgan Healthcare Conference
04 janv. 2023 16h41 HE
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the...
Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update
14 nov. 2022 16h30 HE
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the...
Surrozen Presents Data on Two Lead Therapeutic Candidates at United European Gastroenterology (UEG) Week
10 oct. 2022 08h00 HE
|
Surrozen, Inc.
SZN-043 preclinical data shows rapid, transient increases in hepatocyte proliferation and was well tolerated in non-clinical toxicology studiesSZN-1326 preclinical data shows improved intestinal...
Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases
06 oct. 2022 08h00 HE
|
Surrozen, Inc.
The collaboration and licensing agreement is Surrozen’s first strategic partnership for one of its compounds in developmentSurrozen's novel antibody-based approach targets Fzd4 biology, which has been...